Biopharma Chromatography Systems Market Analysis | 2026-2030

Biopharma Chromatography Systems Market Size & Opportunities

Global Demand Analysis & Sales Opportunities

• The annual demand for biopharma chromatography systems was USD 4.0 billion in 2025 and is expected to reach USD 4.2 billion in 2026, growing 5% year-over-year.

• During the forecast period (2026-2030), the market is expected to grow at a CAGR of 9.4%. Annual demand will reach USD 6.0 billion in 2030, representing approximately 50% growth over the base year.

• As per the market analysis, during 2026-2030, the biopharma chromatography systems industry is expected to generate a cumulative sales opportunity of USD 25.3 billion.

Sharpen Your Strategies by Knowing the Opportunity Pockets. Get Free Sample Here.

High-Growth Market Segments

A comprehensive Biopharma Chromatography Systems Market analysis indicates that segment-level performance varies significantly based on evolving market trends.

• North America is expected to remain the dominant region for the biopharma chromatography systems market during the forecast period.

• By media type, liquid chromatography is expected to maintain its dominance and continue to lead the market in the coming years.

• By end-user type, CMO is anticipated to be the fastest-growing segment, while biopharmaceutical companies remain the largest contributors to overall market revenue.

Biopharma Chromatography Systems Market Statistics

Have a look at the sales opportunities presented by the biopharma chromatography systems market in terms of growth and market forecast.

Biopharma Chromatography Systems Market Data & Statistics

Want to Explore the Market Opportunities? Get Free Sample Here.

Introduction

What is a Biopharma Chromatography System?

A biopharma chromatography system is a specialized laboratory and manufacturing instrument designed to separate, purify, and analyse biological molecules-including proteins, monoclonal antibodies (mAbs), vaccines, enzymes, and gene therapy products-based on differences in their physical and chemical properties. These systems operate on the principle of differential migration, using a stationary phase (column media or membrane) and a mobile phase (liquid solvent or buffer) to resolve complex biological mixtures into highly pure components.

In biopharmaceutical manufacturing, chromatography systems are the backbone of downstream processing. The most widely adopted platform is liquid chromatography, encompassing High-Performance Liquid Chromatography (HPLC), Ultra-High-Performance Liquid Chromatography (UHPLC), Low-Pressure Liquid Chromatography (LPLC), and Flash Chromatography. These are applied across affinity capture, ion exchange polishing, and size exclusion final purification steps-all critical to achieving regulatory-grade purity for therapeutic biologics.

The market is witnessing growing adoption of single-use chromatography systems. Single-use systems significantly reduce cleaning validation requirements.. This trend, combined with the explosive growth of mAbs, GLP-1 drugs, and cell & gene therapies, is creating substantial and sustained demand for advanced chromatography platforms globally.

As a result, the market growth trajectory remains robust, supported by ongoing innovation in resin chemistry, AI-powered data management, and continuous bioprocessing integration.

Market Dynamics

Market Drivers

The biopharma chromatography systems market analysis indicates strong market demand, supported by emerging trends. Below are key factors influencing the overall market size.

Surge in Monoclonal Antibodies, GLP-1 Therapies, and Cell & Gene Therapies

• The continued expansion of the biologics pipeline remains one of the strongest drivers of chromatography system demand. Monoclonal antibodies (mAbs), which require protein A affinity chromatography as a standard capture step, represent the largest class of biologic therapeutics globally. Every commercial mAb product requires multiple purification stages, directly driving demand for chromatography systems, resins, columns, and associated consumables.

• The rapid growth of GLP-1 receptor agonists, led by blockbuster therapies such as tirzepatide and semaglutide, has significantly increased demand for downstream purification infrastructure. Since peptide purification relies extensively on preparative liquid chromatography and HPLC systems, growing production volumes are creating substantial opportunities for chromatography equipment suppliers and service providers.

• Cell and gene therapies continue to expand the scope of biopharmaceutical purification requirements. These advanced therapeutic modalities require highly specialized purification processes for viral vectors, plasmid DNA, and other complex biological materials, supporting demand for next-generation chromatography systems and innovative resin technologies.

Rapid Expansion of Contract Manufacturing Organizations (CMOs)

• The increasing outsourcing of biopharmaceutical manufacturing activities is accelerating demand for flexible and scalable chromatography platforms within CMO facilities. As CMOs serve multiple customers and therapeutic programs simultaneously, they require purification systems capable of supporting rapid product changeovers and diverse manufacturing workflows.

• The growing adoption of single-use bioprocessing technologies is further strengthening demand for modular chromatography solutions. Single-use platforms help reduce cleaning requirements, improve operational flexibility, and support efficient multi-product manufacturing environments, making them particularly attractive for contract manufacturing operations.

AI Integration and Digitalization of Chromatography Workflows

• A major 2025 market trend is the integration of artificial intelligence and advanced data management into chromatography operations. Shimadzu's September 2025 launch of LabSolutions Detect-an AI-powered anomaly detection software for liquid chromatography-and Thermo Fisher's release of Chromeleon 7.4 exemplify the industry's movement toward intelligent, connected purification platforms.

• Automation and AI-driven process optimization reduce manual intervention, improve batch-to-batch reproducibility, and accelerate regulatory submissions-capabilities increasingly critical as biopharmaceutical manufacturers face pressure to compress time-to-market for complex biological therapies.

Market Challenges

High Capital Cost and Post-Pandemic Inventory Correction

• Biopharma chromatography systems require significant capital investment, particularly for large-scale liquid chromatography platforms and integrated downstream processing solutions. For small and mid-sized biopharmaceutical companies, the high upfront cost of equipment can act as a barrier to adoption.

Resin and Column Qualification Complexity

• Switching chromatography resins or columns in a validated biopharmaceutical manufacturing process requires extensive requalification and regulatory documentation, creating high switching costs. This inertia can slow the adoption of newer, higher-performance materials-even when performance advantages are clear. For new entrants and smaller biotechs, the complexity and timeline of qualification processes remain a meaningful barrier to technology adoption.

Align with the Mega Trends Shaping the Industry. Get Free Sample Here.

Segment Analysis

Get Insights on High-Growth Segments. Get Free Sample Here

By Media Type

• Liquid chromatography systems dominate the biopharma chromatography market due to their versatility, superior separation efficiency, and compatibility with the full spectrum of biologics-from small peptides to large viral vectors. HPLC and UHPLC platforms deliver the resolution and throughput required for both analytical quality control and preparative purification, while LPLC and Flash Chromatography systems serve large-volume capture steps in process-scale manufacturing.

• The growing application of liquid chromatography in GLP-1 purification, as well as its expansion into cell and gene therapy workflows, positions this segment for sustained growth across the forecast period

By System Type

• Multi-use chromatography systems maintain market leadership due to their high precision, quantitative reproducibility, and cost-per-run economics at commercial scale. These systems-particularly validated HPLC/UHPLC platforms-are deeply embedded in biopharmaceutical analytical laboratories and large-scale manufacturing facilities.

• Single-use chromatography systems are the fastest-growing segment, driven by their adoption among CMOs and flexible manufacturing facilities. They eliminate cleaning validation, reduce cross-contamination risk in multi-product facilities, and offer faster campaign changeover

By End-User Type

• Biopharmaceutical companies represent the largest end-user segment by revenue, underpinned by in-house R&D and commercial manufacturing operations spanning mAbs, vaccines, recombinant proteins, and emerging cell & gene therapies.

• CMO is expected to be the fastest-growing end-user segment, while biopharmaceutical companies are expected to remain the largest revenue contributors through the forecast period.

• Life Sciences & Academic Research represents a steady-growth segment, with demand driven by R&D spending in drug discovery, biosimilar development, and precision medicine research

Regional Analysis

• North America is expected to maintain its dominance throughout the forecast period, anchored by the world's largest biopharmaceutical industry, robust FDA-regulated manufacturing infrastructure, and the presence of global market leaders including Thermo Fisher Scientific, Waters Corporation, Agilent Technologies, and Repligen Corporation.

• Asia-Pacific is projected to register the fastest growth, driven by rapid industrialization of biopharma manufacturing in China, India, and Japan. China's rapidly expanding biologics and innovative drug development ecosystem is fueling substantial investment in downstream purification infrastructure.

• Europe represents a mature but innovation-driven market, with Germany, France, and the UK home to significant biopharmaceutical research and manufacturing operations. The region is a key hub for continuous bioprocessing technology development and EMA-driven regulatory science

Get Country/Region Specific Report. Contact Us Here.

Competitive Landscape

The top 10 companies collectively account for a significant share of the global biopharma chromatography systems market, reflecting the presence of several well-established industry leaders alongside a broad base of specialized participants

The following are the key players in the biopharma chromatography systems market

• Thermo Fisher Scientific Inc.
• Waters Corporation
• Agilent Technologies Inc.
• Shimadzu Corporation
• Danaher Corporation (Cytiva)
• Sartorius AG
• Repligen Corporation
• PerkinElmer, Inc. (Revvity)
• Merck KGaA (MilliporeSigma)
• Bio-Rad Laboratories, Inc

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Please write to us at sales@stratviewresearch.co

Have the Competitive Edge with Our Intelligence. Get Free Sample Here.

Recent Mergers & Acquisitions

Recent mergers & acquisitions and other developments in the biopharma chromatography systems market reflect evolving market trends and impact the competitive landscape. Below are key recent developments:

Recent Product Developments:

• In September 2025, Thermo Fisher Scientific released Chromeleon 7.4, an updated enterprise chromatography and mass spectrometry data system designed to centralize workflows and data management at scale, reflecting the industry's push toward intelligent, connected purification operations.

• In September 2025, Shimadzu Corporation launched LabSolutions Detect, an AI-powered anomaly detection software for liquid chromatography, enabling automated flagging of impurities and run issues in LC data.

Recent Market M&As and Strategic Acquisitions:

• In September 2025, Thermo Fisher Scientific completed its acquisition of Solventum's Purification & Filtration Business for approximately USD 4.0 billion, directly strengthening its position in bioprocessing and downstream purification markets.

• In December 2024, CatSci Ltd. acquired Reach Separations, a specialist chromatography provider focused on the analysis and purification of therapeutics, reflecting continued consolidation among specialized chromatography service providers.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market.

The following are the key features of the report

• Market structure: Overview, industry life cycle analysis, supply chain analysis.

• Market environment analysis: Growth drivers and constraints, Porter's five forces analysis, SWOT analysis.

• Market trend and forecast analysis.

• Market segment trend and forecast.

• Competitive landscape and dynamics: Market share, product portfolio, new product launches, etc.

• Post-pandemic recovery curve and demand normalization analysis.

• Attractive market segments and associated growth opportunities.

• Emerging trends in single-use systems, AI-integrated platforms, and continuous bioprocessing.

• Strategic growth opportunities for existing and new players.

• Key success factors

Want a Report Tailor-Made to Your Objectives? Speak with Our Analyst

Market Segmentation

The biopharma chromatography systems market is segmented into the following categories

Biopharma Chromatography Systems Market, By System Type

• Single-Use Systems

• Multi-Use System

Biopharma Chromatography Systems Market, By Media Type

• Liquid (HPLC, UHPLC, LPLC, Flash Chromatography, and Others)

• Gas

Biopharma Chromatography Systems Market, By End-User Type

• Biopharmaceutical Companies

• Life Sciences & Academic Research

• CM

Biopharma Chromatography Systems Market, By Region

• North America (Country Analysis: The USA, Canada, and Mexico)

• Europe (Country Analysis: Germany, France, The UK, and Rest of Europe)

• Asia-Pacific (Country Analysis: China, Japan, India, and Rest of Asia-Pacific)

• Rest of the World (Country Analysis: Brazil, Saudi Arabia, and Others

Looking for a Deep Dive? Speak with Our Analyst

Research Methodology

• This strategic assessment report from Stratview Research provides a comprehensive analysis that reflects today's biopharma chromatography systems market realities and future market possibilities for the forecast period (2026-2030).

• The report segments and analyzes the market in the most detailed manner to provide a panoramic view of the market.

• This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research's internal database and statistical tools.

• More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.

• We conducted more than 15 detailed primary interviews with market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com